AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have earned an average rating of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $42.38.

A number of brokerages have weighed in on ANAB. Wells Fargo & Company raised their price objective on AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Johnson Rice restated a “buy” rating on shares of AnaptysBio in a report on Wednesday, March 26th. JPMorgan Chase & Co. raised their price objective on AnaptysBio from $36.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Wedbush restated an “outperform” rating and issued a $40.00 price objective on shares of AnaptysBio in a report on Thursday, May 29th. Finally, Guggenheim restated a “buy” rating and issued a $90.00 price objective (up previously from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $21.27 on Thursday. The stock’s fifty day moving average is $19.95 and its two-hundred day moving average is $18.31. The firm has a market capitalization of $624.91 million, a P/E ratio of -3.50 and a beta of -0.20. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.02. The company had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, equities analysts forecast that AnaptysBio will post -6.08 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has initiated a share repurchase program on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE raised its holdings in AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 979 shares during the period. Farther Finance Advisors LLC raised its holdings in AnaptysBio by 9,778.9% in the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,858 shares during the period. Tower Research Capital LLC TRC raised its holdings in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 1,531 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in AnaptysBio in the 4th quarter valued at about $40,000. Finally, AlphaQuest LLC raised its holdings in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 4,237 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.